Compare SFHG & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFHG | AIDX |
|---|---|---|
| Founded | 1993 | N/A |
| Country | Hong Kong | United States |
| Employees | 226 | 14 |
| Industry | Publishing | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 9.2M |
| IPO Year | N/A | N/A |
| Metric | SFHG | AIDX |
|---|---|---|
| Price | $2.36 | $0.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.4K | ★ 320.5K |
| Earning Date | 10-30-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.54 |
| 52 Week High | $3.17 | $14.09 |
| Indicator | SFHG | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 30.97 |
| Support Level | $2.26 | $0.54 |
| Resistance Level | $2.60 | $1.00 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 16.09 | 7.34 |
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.